Furthermore, while there are data showing correlation of sPD-L1 with outcome in patients with DLBCL [31], the clinical impact of sPD-L1 in the high-risk subgroup in combination with sPD-1 was not previously addressed. Here, HOXD13 is linked to diffuse large B-cell lymphoma.